Financiere de Tubize SA
XBRU:TUB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Financiere de Tubize SA
Cash from Operating Activities
Financiere de Tubize SA
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Financiere de Tubize SA
XBRU:TUB
|
Cash from Operating Activities
-€3.4m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
7%
|
|
|
Ucb SA
XBRU:UCB
|
Cash from Operating Activities
€2.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Hyloris Pharmaceuticals SA
XBRU:HYL
|
Cash from Operating Activities
-€7m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Financiere de Tubize SA
Glance View
Nestled in the heart of Belgium, Financiere de Tubize SA stands as a distinctive player in the world of investment holding companies, anchored in its robust shareholding strategy. Unlike many investment entities that diversify their portfolios across industries, Tubize has channeled its focus largely into the pharmaceutical sector through its significant shareholding in UCB, a global biopharmaceutical giant. This singular focus reflects a strategic commitment to capitalize on the growth and innovations within the healthcare industry, leveraging UCB's extensive research capabilities and expansive market presence. By holding a concentrated position in a company with established credentials in developing treatments for severe diseases, Tubize essentially acts as a conduit for investors to gain exposure to the burgeoning potential of biopharmaceutical advancements. The financial success of Financiere de Tubize SA is intricately tied to the performance of UCB. As UCB thrives and expands through its innovative drug developments and strategic market expansions, Tubize enjoys a consistent flow of dividends and capital appreciation. This dividend income underpins Tubize's operational model, allowing it to reinvest in its core holdings and distribute earnings to its own shareholders, thereby creating a cyclical flow of wealth generation and sustainability. Tubize's approach is akin to a watchful guardian, closely monitoring UCB's strategic paths while maintaining an investment structure that keeps administrative and operational costs minimal. Through such a streamlined focus, Financiere de Tubize SA offers investors a targeted and long-term pathway into the pharmaceutical sector, marked by careful oversight and strategic clarity.
See Also
What is Financiere de Tubize SA's Cash from Operating Activities?
Cash from Operating Activities
-3.4m
EUR
Based on the financial report for Dec 31, 2025, Financiere de Tubize SA's Cash from Operating Activities amounts to -3.4m EUR.
What is Financiere de Tubize SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
7%
Over the last year, the Cash from Operating Activities growth was -63%. The average annual Cash from Operating Activities growth rates for Financiere de Tubize SA have been -45% over the past three years , -10% over the past five years , and 7% over the past ten years .